Canine CAR-T Cell Characterization Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs is committed to providing canine CAR-T characterization validation services to best suit the client's program requirements.

Importance of CARTs Characterization Validation

Preclinical studies reveal the promise and challenges of CAR-T development and therapy. CARTs preclinical evaluation, including a range of responses, such as CARTs activation and exhaustion, tumor killing, and cytokine production, is crucial to the development and optimization of CAR-T cell therapies. These comprehensive evaluation tests usually need to be carried out through multiple dimensions and need to take into account multiple influencing factors. For example, the selection of experimental types, the selection of tumor cells in vitro, the establishment of experimental models in vivo, and so on.

Fig.1 Canine CAR-T model and preclinical evaluation. (Duncan, et al., 2022)

Our Canine CAR-T Characterization Validation Service

Leveraged by advanced technology platforms and years of experience, Creative Biolabs has launched a full range of evaluation analysis services for global customers to facilitate canine CAR-T research. Our services are featured with the following assays. In addition to these assays, we also provide customized development experiments according to customers' project needs.

*CART In Vitro* Assay Service**
CAR Expression Test	CellRapeutics™ Cytokine Release Test	CellRapeutics™ Proliferation Test
T Cell-Mediated Tumor Cell Lysis Assay	CellRapeutics™ Multiplex Cytokine and Chemokine Assay	Antigen-Specific T Cell Activation Assay
*CAR-T Preclinical In Vivo* Assay**
Efficacy Test of CAR-T	Viability and Bio-distribution Study of CAR-T	Toxicity Evaluation of CAR-T

Published Data

Paper Title: Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B cell lymphoma.
Summary: The researchers designed and established 2^nd and 3^rd cCD20-ζ CAR-T cells using the retrovirus transfection method. The 2^nd and 3^rd cCD20-ζ CAR-T cells showed cytotoxicity and target specificity in in-vitro functional evaluation.
Technology: Retroviral transfection;
Cell Type: Canine PBMC;
In Vitro Tumor Model: Canine B cell lymphoma cell line CLBL-1;
Results:

Fig.2 Canine CARTs subtype analysis by FACS after T cell stimulation with artificial APCs. (Sakai, et al., 2020)

Fig.3 In vitro cytotoxic activity of canine CD20 CAR-T cells. (Sakai, et al., 2020)

Fig.4 Cytokine detection after canine CARTs expansion by various treatments. (Sakai, et al., 2020)

Fig.5 Phenotypic and functional analysis of cryopreserved canine CAR-T cells. (Sakai, et al., 2020)

Frequently Asked Questions

Q1. For canine CAR-T development, how does Creative Biolabs select target tumor cells for different targets?

A: In the development, we will first communicate with the customer whether there are relevant reference data or literature. If the target is really rare and appropriate tumor cells cannot be found, we will construct overexpressed cell lines to meet the experimental requirements.

Q2. How does Creative Biolabs secure the source of cells for canine CAR-T development?

A: We strictly abide by the FDA requirements. PBMC samples collected from blood donors on the day of product collection are tested in accordance with FDA requirements for blood for transfusion.

If there is any query, please contact us for more details about the canine CAR-T cell characterization service.

References

Duncan, B. B.; et al. Applying a clinical lens to animal models of CAR-T cell therapies. Molecular Therapy-Methods & Clinical Development. 2022, 27, 17-31.
Sakai, O.; et al. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma. Veterinary and comparative oncology. 2020, 18(4), 739-752.